Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has issued an announcement.
Clover Biopharmaceuticals Ltd. announced the U.S. FDA clearance for its Investigational New Drug application and the initiation of a Phase I revaccination clinical trial for its RSV vaccine candidate, SCB-1019. This trial, enrolling older adults who previously received GSK’s RSV vaccine, aims to evaluate the safety and immunogenicity of SCB-1019. The company is also planning a Phase I trial in 2025 for a combination vaccine involving RSV and other respiratory viruses, indicating its strategic expansion in the vaccine market.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company in the biotechnology industry, focusing on the development of innovative vaccines and biologics. It utilizes its proprietary Trimer-Tag vaccine technology platform to create vaccine candidates, with a market focus on addressing infectious diseases.
YTD Price Performance: 34.85%
Average Trading Volume: 1,618,911
Technical Sentiment Signal: Hold
Current Market Cap: HK$421.5M
Find detailed analytics on 2197 stock on TipRanks’ Stock Analysis page.